




## Supplementary Figures




**Supplementary figure S1. The role of USP family members in MDA-MB-468 cells under chemo-drug treatment.** (A) Analysis of colony formation in MDA-MB-468 cells with transient expression of USP7 under doxorubicin and paclitaxel treatment, respectively. Analysis of cell viability (B) and apoptotic (C, D) assays in MDA-MB-468 cells with transient expression of USP7, USP12, and USP21 under doxorubicin (left) and paclitaxel (right) treatment, respectively (F) Expressions of ABCB1, USP7, USP12, and USP21 in breast cell lines. \*:  $P$ -value  $<0.05$ , compared with control cells.




**Supplementary figure S2. The role of USP7 in chemoresistant activity of MDA-MB-468 cells with chemo-drug resistance.** (A) Analysis of the viability of doxorubicin-resistant MDA-MB-468 (left) and paclitaxel-resistant MDA-MB-468 (right) cells treated with 2 nM of doxorubicin or 2 nM of paclitaxel for 7 days compared with parental MDA-MB-468 cells, assessed using MTT assays. Analysis of colony formation (B), viability (C), and apoptotic (D, E) activities in doxorubicin- and paclitaxel-resistant MDA-MB-468-USP7-silencing cells under doxorubicin and paclitaxel treatment. (F) Cell viability of doxorubicin- and paclitaxel-resistant MDA-MB-468-USP7-silencing cells with re-expression of USP7 under 10 nM of doxorubicin and paclitaxel treatment, respectively. \*  $P$ -value  $<0.05$ , compared with control cells.




**Supplementary figure S3. The role of USP7 in migration and invasive activity of chemo-drug-resistant MDA-MB-468 cells.** Analysis of migration (A, B) and invasive (C, D) activities in doxorubicin- and paclitaxel-resistant MDA-MB-468-USP7-silencing cells. Analysis of migration (E) and invasive (F) activities in doxorubicin- and paclitaxel-resistant MDA-MB-468-USP7-silencing cells with re-expression of USP7. \*:  $P$ -value  $<0.05$ , compared with control cells.




**Supplementary figure S4. The effect of USP7 inhibitor on chemo-drug-resistant MDA-MB-468 cells.** Analysis of viability (A), and apoptotic activities (B, C) in doxorubicin- and paclitaxel-resistant MDA-MB-468 cells under GNE-6776 treatments. \*:  $P$ -value  $<0.05$ , compared with untreated cells.



**Supplementary figure S5. The effect of USP7 inhibitor on migration and invasive activities of chemo-drug-resistant MDA-MB-468 cells.** Analysis of migration (A, B) and invasive (C, D) activities in doxorubicin- and paclitaxel-resistant MDA-MB-468 cells under GNE-6776 treatment. \*:  $P$ -value  $<0.05$ ,



**Supplementary figure S6. Correlation between USP7 and ABCB1 *in vivo*.** Immunohistochemistry staining analysis for ABCB1 in the xenograft system injected with doxorubicin- and paclitaxel-resistant MDA-MB-231-USP7-silencing cells by using anti-ABCB1 antibodies. Scale bar represented 200 μm.



**Supplementary figure S7. Expression of proliferation markers, PI3K/AKT/mTOR signaling, and cell cycle markers in chemo-drug-resistant MDA-MB-468 cells.** The levels of proliferation markers (Ki67 and PCNA), PI3K/AKT/mTOR signaling (p110a, p110b, phosphor-AKT, AKT, phosphor-mTOR, and mTOR), and cell cycles markers (CDK1, CDK2, CDK4, CDK6, Cyclin E1, and Cyclin B1) in doxorubicin- and paclitaxel-resistant MDA-MB-468 cells under 10 mM of GNE-6776 treatment.

## Supplementary Method

### Immunohistochemistry (IHC)

Four μm thick sections of all tissue were cut from the paraffin-embedded specimens for IHC staining. The samples were fixed in 4% paraformaldehyde solution for 24 h. the IHC was performed by by using Mouse and Rabbit Specific HRP/DAB IHC Detection Kit - Micro-polymer (Abcam, ab236466). Briefly, the endogenous peroxidase activity was eliminated with 3% hydrogen peroxide and then incubated with 1% bovine serum albumin and 5% normal goat serum for the blocking step. After reacting with a biotinylated secondary antibody for 1.5 h, antigen-antibody reactions were visualized using streptavidin-horseradish peroxidase conjugate with DAB chromogen. All slides were counterstained with hematoxylin. The antibodies used in IHC were listed in supplementary table 1.



## Supplementary Tables

**Supplementary Table S1. List of proteins tested by and characteristics of the corresponding antibodies**

Protein	Assay	Origin	Dilution	Incubation period
E-cadherin	WB	#3195, Cell signaling	1:500	4°C, Overnight
Vimentin	WB	A19607, ABclonal	1:500	4°C, Overnight
N-cadherin	WB	#610920, BD biosciences	1:500	4°C, Overnight
Plakoglobin	WB	ab184919, abcam	1:2000	4°C, Overnight
$\beta$ -actin	WB	#3700, Cell Signaling	1:2000	4°C, Overnight
Bcl-2	WB	#2872, Cell Signaling Technology	1:500	4°C, Overnight
Bcl-xL	WB	#2764, Cell Signaling Technology	1:500	4°C, Overnight
BAX	WB	#2772, Cell Signaling Technology	1:500	4°C, Overnight
BIM	WB	#2819, Cell Signaling Technology	1:500	4°C, Overnight
cleaved PARP	WB	#5625, Cell Signaling Technology	1:500	4°C, Overnight
cleaved Caspase-7	WB	#9491, Cell Signaling Technology	1:500	4°C, Overnight
cleaved Caspase-3	WB	#9661, Cell Signaling Technology	1:500	4°C, Overnight
cleaved Caspase-9	WB	#9505, Cell Signaling Technology	1:500	4°C, Overnight
Flag	WB,IP	TA50011-100,Origene	1:500	4°C, Overnight
HA	WB, IP	#05-904, millipore	1:500	4°C, Overnight
USP7	WB	A300-033A, Bethyl	1:2000	4°C, Overnight
Ub K48	WB	#05-1307, millipore	1:500	4°C, Overnight
t-Bid	WB	ab10640, abcam	1:500	4°C, Overnight
ABCB1	WB	#12683, Cell Signaling Technology	1:1000	4°C, Overnight
ABCG2	WB	E-AB-30393, Elabscience	1:500	4°C, Overnight
ABCC1	WB	#14685, Cell Signaling Technology	1:500	4°C, Overnight
GST	WB	#13-6700, Thermo Fisher	1:2000	4°C, Overnight
ABCB1	IHC	#12683, Cell Signaling Technology	1:400	4°C, Overnight
PI3K p100 $\alpha$	WB	#4249, Cell signaling	1:500	4°C, Overnight
PI3K p100 $\beta$	WB	#3011, Cell signaling	1:500	4°C, Overnight
phospho-mTOR	WB	#2976, Cell Signaling	1:500	4°C, Overnight
mTOR	WB	#2983, Cell Signaling	1:500	4°C, Overnight
phospho-AKT	WB	#4060, Cell Signaling	1:500	4°C, Overnight

AKT	WB	#9272, Cell Signaling	1:500	4°C, Overnight
Ki67	WB	ab92742, abcam	1:2000	4°C, Overnight
PCNA	WB	GTX100539, Genetex	1:400	4°C, Overnight
CDK1	WB	#9116, Cell signaling	1:2000	4°C, Overnight
CDK2	WB	#2546, Cell signaling	1:2000	4°C, Overnight
CDK4	WB	#12790, Cell signaling	1:1000	4°C, Overnight
CDK6	WB	#13331, Cell signaling	1:2000	4°C, Overnight
Cyclin E1	WB	#4129, cell signaling	1:1000	4°C, Overnight
Cyclin B1	WB	#4138, cell signaling	1:1000	4°C, Overnight
ABCB1	WB	#12683, Cell Signaling Technology	1:1000	4°C, Overnight

Abbreviations:

WB, Western blot; IP: Immunoprecipitation; IHC: Immunohistochemistry

**Supplementary Table S2. Sequence of the oligonucleotides for Quantitative real-time PCR assays**

Target		5' to 3'
18s rRNA	Forward	<b>GTAACCCGTTGAACCCCAT</b>
	Reverse	<b>CCATCCAATCGGTAGTAGCG</b>
ABCB1 mRNA	Forward	<b>GCTCCTGACTATGCCAAAGC</b>
	Reverse	<b>TCTTCACCTCCAGGCTCAGT</b>

**Supplementary Table S3. List of plasmid constructs used.**

Plasmid	Vector
Flag-USP21	pFlag-CMV2
Flag-USP12	pFlag-CMV6
Flag-USP7	pFlag-CMV2
Flag-USP7 1-500	pFlag-CMV2
Flag-USP7 500-1100	pFlag-CMV2
GST-USP7 1-209	pGEX4T1
GST-USP7 210-500	pGEX4T1